Moonshot Projects In Life Sciences Strategy Can Lift UK Over Brexit Hurdle
Executive Summary
The long-awaited UK Life Sciences Strategy, part of the industrial strategy proposed after the May government took office in summer 2016, was released today. With input from major medtech organizations and UK-based pharma groups it charts a course ahead for the £64bn national life-sciences industry as the UK seeks to embrace its post-EU future.
You may also be interested in...
UK Life Sciences Industrial Strategy Is Starting To Show Its Value In The Medtech Arena
UK strategies that have sought to maximize the partnership potential of medtech innovators and the country's National Health Service have often not lasted long enough to prove their worth. But Neil Mesher, Philips CEO of UK and Ireland, says the Life Sciences Industrial Strategy might just be different.
Philips Hails 'New Day' For Digital Diagnosis And AI As UK Govt Supports Five Specialist Centers
Several major global health-care diagnostics groups have won bids to spearhead five new UK centers of excellence for digital pathology and imaging, including radiology and using AI medical advances. A key aim of the initiative, provided for under the UK Life Sciences Industrial Strategy, is to create a brand new commercial sector around the development of AI for diagnostics, says Neil Mesher, CEO of Philips UK and Ireland, which has a role in two of the centers.
Life-Sciences Industry Would Pay £10M In Fees Each Year To UK NICE Under Proposal
England’s department of health is again consulting on plans to allow the health technology appraisal body NICE to charge companies for conducting appraisals.